CG Oncology director sells 1,000 exercised shares

CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share.

Accepted by SEC EDGAR 07/17/2026 - 04:15 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

CG Oncology, Inc. director Leonard E. Post exercised stock options for 1,000 shares of Common Stock at $0.60 per share and on July 15, 2026 sold 1,000 shares at $71.17 per share. The sale was effected under a Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, he held no Common Stock directly and 105,077 fully vested Director Stock Options.

Insider Trade Summary 10b5-1

Exercise and Sale: 1,000 shares ($71K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider POST LEONARD E

Role Director

Sold 1,000 shs ($71K)

Approx. gross sale proceeds $71K

Approx. exercise cost $600.00

Approx. pre-tax spread $71K

Type	Security	Shares	Price	Value
Exercise	Director Stock Option (right to buy) F2	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$0.60	$600.00
Sale	Common Stock F1	1,000	$71.17	$71K

Holdings After Transaction: Director Stock Option (right to buy) — 105,077 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
2. F2. Fully vested

Key Figures

Shares sold: 1,000 shares Sale price: $71.17 per share Shares acquired via option exercise: 1,000 shares +3 more

6 metrics

Shares sold 1,000 shares Common Stock sold on 2026-07-15 at $71.17 per share

Sale price $71.17 per share Price for 1,000 Common Stock shares in a sale coded S

Shares acquired via option exercise 1,000 shares Common Stock acquired through option exercise on 2026-07-15

Option exercise price $0.60 per share Exercise price for Director Stock Option converting into 1,000 Common Stock shares

Options remaining 105,077 options Director Stock Options held after exercising 1,000 options

Option expiration date 2028-07-08 Expiration date of the reported Director Stock Option series

Key Terms

Rule 10b5-1 trading plan, Director Stock Option (right to buy), derivative security

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Director Stock Option (right to buy) financial

"Director Stock Option (right to buy) reported as a derivative security"

derivative security financial

"Exercise or conversion of derivative security coded as transaction type M"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CGON director Leonard E. Post report?

Leonard E. Post reported exercising 1,000 stock options for CG Oncology Common Stock at $0.60 per share and selling 1,000 shares at $71.17 per share on July 15, 2026, leaving no direct Common Stock holdings and remaining option holdings.

How many CGON shares did Leonard E. Post sell and at what price?

Leonard E. Post sold 1,000 shares of CG Oncology Common Stock at an average price of $71.17 per share. The transaction was coded as a sale in an open-market or private transaction and occurred on July 15, 2026.

Were Leonard E. Post’s CGON share sales under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Leonard E. Post on March 5, 2026. Such pre-arranged plans automate trades according to preset instructions, limiting discretionary timing.

What CGON stock options does Leonard E. Post still hold after this transaction?

After exercising 1,000 options, Leonard E. Post held 105,077 Director Stock Options. These options are reported as fully vested and relate to CG Oncology Common Stock, with the specific option series shown expiring on July 8, 2028.

At what price were CGON options exercised in Leonard E. Post’s recent transaction?

The options were exercised at an exercise price of $0.60 per share for 1,000 shares of CG Oncology Common Stock. The exercise reduced the option position by 1,000 and simultaneously created 1,000 shares that were then sold the same day.

Does Leonard E. Post hold any CGON Common Stock after the reported transactions?

No. Following the reported sale of 1,000 shares, Leonard E. Post’s direct holdings of CG Oncology Common Stock are reported as 0 shares. His remaining exposure comes from 105,077 outstanding stock options rather than direct share ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

POST LEONARD E

(Last) (First) (Middle)

C/O CG ONCOLOGY, INC.

3000 PEGASUS PARK DRIVE, SUITE 1640

(Street)

DALLAS TEXAS 75247

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CG Oncology, Inc. [ CGON ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/15/2026		M		1,000	A	$0.6	1,000	D
Common Stock	07/15/2026		S(1)		1,000	D	$71.17	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (right to buy)	$0.6	07/15/2026		M			1,000	(2)	07/08/2028	Common Stock	1,000	$0	105,077	D

Explanation of Responses:

1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.

2. Fully vested

	/s/ Joshua F. Patterson, Attorney-in-Fact for Leonard Post	07/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)